NCT02876354View on ClinicalTrials.gov

Risk Factors for Vascular Calcifications in Hemodialysis Patients: to What Extent is Vitamin K2 Deficiency Involved?

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
Vascular Calcifications
Interventions
DRUG

Menaquinone

Patients on hemodialysis will be supplemented by 360 μg /d of menaquinone for 4 weeks. At baseline they will have a lateral abdominal X-Ray and dosage of dp-ucMGP. At the end of the study patients will have a second measurement of dp-ucMGP levels.

Trial Locations (1)

Unknown

Saint-Georges Hospital, Ajaltoun

All Listed Sponsors
lead

Saint-Joseph University

OTHER

NCT02876354 - Risk Factors for Vascular Calcifications in Hemodialysis Patients: to What Extent is Vitamin K2 Deficiency Involved? | Biotech Hunter | Biotech Hunter